400 Fifth Avenue
Suite 210
Waltham, MA 02451
United States
510 745 1700
https://www.ardelyx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 267
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Michael G. Raab | President, CEO & Director | 1.28M | N/A | 1965 |
Ms. Susan Rodriguez | Chief Commercial Officer | 760.77k | N/A | 1964 |
Dr. Laura A. Williams M.D., M.P.H. | Chief Medical Officer | 873.8k | N/A | 1964 |
Mr. Robert Felsch | Senior VP of Finance & Chief Accounting Officer | N/A | N/A | N/A |
Ms. Elizabeth A. Grammer Esq. | Chief Legal & Administrative Officer and Secretary | 623.7k | N/A | 1964 |
Ms. Caitlin Lowie | Vice President of Corporate Communications & Investor Relations | N/A | N/A | N/A |
Ms. Charon Spencer Sr. | Chief Human Resources Officer | N/A | N/A | N/A |
Mr. David P. Rosenbaum | Chief Development Officer | 645.4k | N/A | 1961 |
Mr. Robert C. Blanks | Chief Regulatory Affairs & Quality Assurance Officer | 590.8k | N/A | 1960 |
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Ardelyx, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 9; Board: 7; Shareholder rights: 8; Compensation: 9.